Regeneus Limited (ASX: RGS)

Regeneus Limited (ASX: RGS) is a clinical-stage regenerative medicine company developing a portfolio of innovative cellular therapies targeting significant unmet medical needs in both human and animal health markets. Initial focus is on osteoarthritis (OA), cancer, inflammatory skin conditions and wound healing. The company’s product pipeline is underpinned by proprietary stem cell and immuno-oncology technologies.

Regeneus Kyocera Progenza knee osteoarthritis OA licence ASX RGS stem cell

Regeneus signs agreement with Kyocera for licensing of Progenza knee osteoarthritis drug to Japanese market

Clinical-stage regenerative medicine company Regeneus (ASX: RGS) has signed a licence and collaboration agreement with Kyocera Corporation to de...
Regeneus ASX RGS Chinese patent biomarkers stem cell therapy monitoring disease progression

Regeneus receives Chinese patent for biomarkers in monitoring disease progression for stem cell therapy

Regenerative medicine company Regeneus (ASX: RGS) has reached a significant milestone in its mission to market its proprietary biomarkers in Chi...
Knee osteoarthritis japanese patent regeneus progenza stem cell technology

Japanese patent office grants key patent for Regeneus’ Progenza stem cell technology

Regeneus (ASX: RGS) today announced that the Japanese patent office has issued a decision to grant a key patent covering the composition, manufa...